Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
MENLO PARK, CA -- (Marketwired) -- 06/02/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven®) to treat triple-negative breast cancer (TNBC) indicate …